Key Takeaways BSX's EP business is expected to grow nearly 15% over the LRP, driven by share gains and ICE entry.BSX's WATCHMAN remains the top LAAC device, with growth tied to positive OPTION and CHAMPION trial results.Boston Scientific's ICTx, its most global cardiovascular unit, targets 10% growth and aims to beat markets.Boston Scientific’s (BSX) Cardiovascular segment operates in a $50 billion market, projected to grow nearly 9% over the 2026-2028 long-range plan (LRP). Management expects the business ...